期刊
ADVANCES IN THERAPY
卷 36, 期 10, 页码 2638-2678出版社
SPRINGER
DOI: 10.1007/s12325-019-01051-z
关键词
Biomarkers; Cytotoxic T-lymphocyte antigen 4 (CTLA-4); DNA damage response (DDR); Immunotherapy; Mismatch repair deficiency (MMR); Programmed death 1 (PD-1); Tumor mutation burden (TMB)
资金
- NIH [R01 CA218802, R21 CA223394]
- V Foundation translation award program [T2018-013]
- DOD [W81XWH-18-1-0196, W81XWH-18-1-0148]
- Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship
- NCI Core Grant [P30 CA006927]
In the last few years, immunotherapy has transformed the way we treat solid tumors, including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable responses and long-term survival benefit has been experienced by many cancer patients, with favorable toxicity profiles of immunotherapeutic agents relative to chemotherapy. Cures have become possible in some patients with metastatic disease. Additional approvals of immunotherapy drugs and in combination with other agents are anticipated in the near future. Multiple additional immunotherapy drugs are in earlier stages of clinical development, and their testing in additional tumor types is under way. Despite considerable early success and relatively fewer side effects, the majority of cancer patients do not respond to checkpoint inhibitors. Additionally, while the drugs are generally well tolerated, there is still the potential for significant, unpredictable and even fatal toxicity with these agents. Improved biomarkers may help to better select patients who are more likely to respond to these drugs. Two key biologically important predictive tissue biomarkers, specifically, PD-L1 and mismatch repair deficiency, have been FDA-approved in conjunction with the checkpoint inhibitor, pembrolizumab. Tumor mutation burden, another promising biomarker, is emerging in several tumor types, and may also soon receive approval. Finally, several other tissue and liquid biomarkers are emerging that could help guide single-agent immunotherapy and in combination with other agents. Of these, one promising investigational biomarker is alteration or deficiency in DNA damage response (DDR) pathways, with altered DDR observed in a broad spectrum of tumors. Here, we provide a critical overview of current, emerging, and investigational biomarkers in the context of response to immunotherapy in solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据